デフォルト表紙
市場調査レポート
商品コード
1006016

血漿分画市場の成長機会・成長予測 (2020-2027年):製品 (アルブミン・免疫グロブリン・凝固第VIII因子・凝固第IX因子)・セクター (公共部門・民間部門)・地域別

Plasma Fractionation Market by Product (Albumin, Immunoglobulins, Coagulation factor VIII, and Coagulation factor IX) and Sector (Public Sector and Private Sector): Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日: | 発行: Allied Market Research | ページ情報: 英文 202 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
血漿分画市場の成長機会・成長予測 (2020-2027年):製品 (アルブミン・免疫グロブリン・凝固第VIII因子・凝固第IX因子)・セクター (公共部門・民間部門)・地域別
出版日: 2021年03月22日
発行: Allied Market Research
ページ情報: 英文 202 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血漿分画の市場規模は予測期間中6.2%のCAGRで推移し、2019年の182億2200万ドルから、2027年には230億600万ドルの規模に成長すると予測されています。

血漿を必要とするさまざまな希少疾患を抱える高齢者人口の増加、免疫グロブリンやα-1-アンチトリプシンの使用の増加、血漿採取センターの急増、政府による血漿分画製剤の普及啓発活動などの要因が同市場の成長を推進しています。一方で、血漿分画製剤のコストの高さが市場のさらなる成長を抑制しています。

当レポートでは、世界の血漿分画の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品・セクター・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターのファイブフォース分析
  • 主要企業の位置付け
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析
  • COVID-19:影響分析

第4章 市場分析・予測:製品別

  • アルブミン
  • 免疫グロブリン
  • 凝固第VIII因子
  • 凝固因子IX
    • 主要市場動向・成長機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第5章 市場分析・予測:セクター別

  • 公的機関
  • 民間部門
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ
    • 主要動向・成長要因・成長機会
    • 市場規模・予測:製品別
    • 市場規模・予測:セクター別
    • 市場規模・予測:国別

第7章 企業プロファイル

  • BAXTER INTERNATIONAL INC.
  • BIO PRODUCTS LABORATORY
  • BIOTEST AG
  • CSL LTD.
  • GRIFOLS SA
  • KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
  • LFB S. A
  • OCTAPHARMA AG
  • SANQUIN BLOOD SUPPLY FOUNDATION
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
図表

LIST OF TABLES

  • TABLE 01.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 02.PLASMA FRACTIONATION MARKET FOR ALBUMIN AND IMMUNOGLOBULIN, BY REGION, 2019-2027 (METRIC TONS)
  • TABLE 03.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII AND COAGULATION FACTOR IX, BY REGION, 2019-2027 (INTERNATIONAL UNITS (IU))
  • TABLE 04.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2019-2027 (METRIC TONS)
  • TABLE 06.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY REGION, 2019-2027 (METRIC TONS)
  • TABLE 08.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY REGION, 2019-2027 (INTERNATIONAL UNITS (IU))
  • TABLE 10.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY REGION, 2019-2027 (INTERNATIONAL UNITS (IU))
  • TABLE 12.PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 13.PLASMA FRACTIONATION MARKET FOR PUBLIC SECTOR, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.PLASMA FRACTIONATION MARKET FOR PRIVATE SECTOR, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.PLASMA FRACTIONATION MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.PLASMA FRACTIONATION MARKET, FOR ALBUMIN AND IMMUNOGLOBULIN, BY REGION, 2019-2027 (METRIC TONS)
  • TABLE 17.PLASMA FRACTIONATION MARKET, FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY REGION, 2019-2027 (MILLION INTERNATIONAL UNITS)
  • TABLE 18.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 19.U.S. PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 20.U.S. PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 21.CANADA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 22.CANADA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 23.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 24.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 25.EUROPE PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 26.GERMANY PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 27.GERMANY PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 28.UK PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 29.UK PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 30.FRANCE PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 31.FRANCE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 32.TURKEY PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 33.TURKEY PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 34.RUSSIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 35.RUSSIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 36.REST OF EUROPE PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 37.REST OF EUROPE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 38.EUROPE PLASMA FRACTIONATION MARKET, 2019-2027 ($MILLION)
  • TABLE 39.EUROPE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 40.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 41.CHINA PLASMA FRACTIONATION MARKET, 2019-2027 ($MILLION)
  • TABLE 42.CHINA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 43.JAPAN PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 44.JAPAN PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 45.INDIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 46.INDIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 47.SOUTH KOREA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 48.SOUTH KOREA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 49.TAIWAN PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 50.TAIWAN PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 51.INDONESIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 52.INDONESIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 53.THAILAND PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 54.THAILAND PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 55.MALAYSIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 56.MALAYSIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 57.VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 58.VIETNAM PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 59.REST OF ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 60.REST OF ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 61.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 62.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 63.LAMEA PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 64.BRAZIL PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 65.BRAZIL PLASMA FRACTIONATION MARKET, BY PRODUCT BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 66.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 67.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 68.REST OF LAMEA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 69.REST OF LAMEA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 70.LAMEA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019-2027 ($MILLION)
  • TABLE 71.LAMEA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019-2027 ($MILLION)
  • TABLE 72.BAXTER: COMPANY SNAPSHOT
  • TABLE 73.BAXTER: PRODUCT SEGMENT
  • TABLE 74.BAXTER: PRODUCT PORTFOLIO
  • TABLE 75.BIO PRODUCTS LABORATORY: COMPANY SNAPSHOT
  • TABLE 76.BIO PRODUCTS LABORATORY: OPERATING SEGMENTS
  • TABLE 77.BIO PRODUCTS LABORATORY: PRODUCT PORTFOLIO
  • TABLE 78.BIOTEST AG: COMPANY SNAPSHOT
  • TABLE 79.BIOTEST AG: OPERATING SEGMENTS
  • TABLE 80.BIOTEST AG: PRODUCT PORTFOLIO
  • TABLE 81.CSL LTD: COMPANY SNAPSHOT
  • TABLE 82.CSL LTD..: OPERATING SEGMENT
  • TABLE 83.CSL LTD..: PRODUCT PORTFOLIO
  • TABLE 84.GRIFOLS: COMPANY SNAPSHOT
  • TABLE 85.GRIFOLS: OPERATING SEGMENTS
  • TABLE 86.GRIFOLS SA: PRODUCT PORTFOLIO
  • TABLE 87.KEDRION: COMPANY SNAPSHOT
  • TABLE 88.KEDRION: OPERATING SEGMENTS
  • TABLE 89.KEDRION: PRODUCT PORTFOLIO
  • TABLE 90.LFB: COMPANY SNAPSHOT
  • TABLE 91.LFB: OPERATING SEGMENTS
  • TABLE 92.LFB: PRODUCT PORTFOLIO
  • TABLE 93.OCTAPHARMA: COMPANY SNAPSHOT
  • TABLE 94.OCTAPHARMA: OPERATING SEGMENTS
  • TABLE 95.OCTAPHARMA: PRODUCT PORTFOLIO
  • TABLE 96.SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
  • TABLE 97.SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
  • TABLE 98.SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
  • TABLE 99.TAKEDA: COMPANY SNAPSHOT
  • TABLE 100.TAKEDA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL PLASMA FRACTIONATION MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 06.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07.MODERATE COMPETITIVE RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING, 2019
  • FIGURE 09.WORLD POPULATION AGED 65 AND OVER (%)
  • FIGURE 10.IMPACT ANALYSIS, PLASMA FRACTIONATION MARKET
  • FIGURE 11.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019 & 2027 (METRIC TONS)
  • FIGURE 13.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019 & 2027 (METRIC TONS)
  • FIGURE 15.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 (INTERNATIONAL UNITS (IU))
  • FIGURE 17.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 (INTERNATIONAL UNITS (IU))
  • FIGURE 19.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR PUBLIC SECTOR, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF PRIVATE SECTOR PLASMA FRACTIONATION MARKET FOR PRIVATE SECTOR, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 21.BAXTER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 22.BAXTER: REVENUE SHARE, BY SEGMENT 2019(%)
  • FIGURE 23.BAXTER: REVENUE SHARE, BY REGION 2019(%)
  • FIGURE 24.BIOTEST AG: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 25.BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 26.BIOTEST AG: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 27.CSL LTD.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.CSL LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 29.CSL LTD.: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 30.GRIFOLS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.GRIFOLS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 32.GRIFOLS: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 33.KEDRION: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 34.KEDRION: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 35.OCTAPHARMA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 37.SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
  • FIGURE 38.SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY REGION, 2018 (%)
  • FIGURE 39.TAKEDA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.TAKEDA: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 41.TAKEDA: REVENUE SHARE, BY REGION, 2020 (%)
目次
Product Code: LI_18943 / A00796

The global plasma fractionation market was valued at $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027.

Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin and immunoglobulins. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals.

Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the market growth. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward the growth of this market.

In addition, favorable government support to spread awareness related to use of plasma derived products also fuels the growth of the plasma fractionation market. However, high cost of plasma derived products restricts the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.

The global plasma fractionation market is segmented on the basis of product, sector, and region. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is bifurcated into public sector and private sector. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Product

  • Albumin
  • Immunoglobulins
  • Coagulation factor VIII
  • Coagulation factor IX

By Sector

  • Public Sector
  • Private Sector

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Turkey
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Taiwan
  • South Korea
  • Indonesia
  • Thailand
  • Malaysia
  • Vietnam
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Kingdom of Saudi Arabia
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Baxter International Inc
  • Bio product laboratory
  • Biotest AG
  • CSL Ltd.
  • Grifols SA
  • Kedrion S.P.A (Kedrion Biopharma Inc.)
  • LFB S. A
  • Octapharma AG
  • Sanquin Blood Supply Foundation
  • Takeda Pharmaceutical Company Limited
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Emergent BioSolutions
  • Green Cross Corporation
  • Centurion Pharma

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
    • 3.3.1.Bargaining power of buyers
    • 3.3.2.Bargaining power of suppliers
    • 3.3.3.Thereat of new entrants
    • 3.3.4.Threat of substitutes
    • 3.3.5.Intensity of competitive rivalry
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
      • 3.5.1.2.Rise in use of immunoglobulins in medicine
      • 3.5.1.3.Increase in number of plasma collection centers across the globe
    • 3.5.2.Restraint
      • 3.5.2.1.High cost of plasma derived products
    • 3.5.3.Opportunity
      • 3.5.3.1.High growth potential in emerging economies
    • 3.5.4.Impact Analysis
  • 3.6.COVID-19 Impact analysis on plasma fractionation market

CHAPTER 4:PLASMA FRACTIONATION MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Albumin
    • 4.2.1.Key market trends and growth opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Immunoglobulins
    • 4.3.1.Key market trends and growth opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Coagulation factor VIII
    • 4.4.1.Key market trends and growth opportunities
    • 4.4.2.Market size and forecast, by country
    • 4.4.3.Market analysis, by country
  • 4.5.Coagulation factor IX
    • 4.5.1.Key market trends and growth opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country

CHAPTER 5:PLASMA FRACTIONATION MARKET, BY SECTOR

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Public Sector
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Private Sector
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:PLASMA FRACTIONATION MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by country
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. plasma fractionation market, by product
      • 6.2.2.1.2.U.S. plasma fractionation market, by sector
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada plasma fractionation market, by product
      • 6.2.2.2.2.Canada plasma fractionation market, by sector
    • 6.2.3.North America market size and forecast, by product
    • 6.2.4.North America market size and forecast, by sector
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by country
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Germany plasma fractionation market, by product
      • 6.3.2.1.2.Germany plasma fractionation market, by sector
      • 6.3.2.2.UK
      • 6.3.2.2.1.UK plasma fractionation market, by product
      • 6.3.2.2.2.UK plasma fractionation market, by sector
      • 6.3.2.3.France
      • 6.3.2.3.1.France plasma fractionation market, by product
      • 6.3.2.3.2.France plasma fractionation market, by sector
      • 6.3.2.4.Turkey
      • 6.3.2.4.1.Turkey plasma fractionation market, by product
      • 6.3.2.4.2.Turkey plasma fractionation market, by sector
      • 6.3.2.5.Russia
      • 6.3.2.5.1.Russia plasma fractionation market, by product
      • 6.3.2.5.2.Russia plasma fractionation market, by sector
      • 6.3.2.6.Rest of Europe
      • 6.3.2.6.1.Rest of Europe plasma fractionation market, by product
      • 6.3.2.6.2.Rest of Europe plasma fractionation market, by sector
    • 6.3.3.Europe market size and forecast, by product
    • 6.3.4.Europe market size and forecast, by sector
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by country
      • 6.4.2.1.China
      • 6.4.2.1.1.China plasma fractionation market, by product
      • 6.4.2.1.2.China plasma fractionation market, by sector
      • 6.4.2.2.Japan
      • 6.4.2.2.1.Japan plasma fractionation market, by product
      • 6.4.2.2.2.Japan plasma fractionation market, by sector
      • 6.4.2.3.India
      • 6.4.2.3.1.India plasma fractionation market, by product
      • 6.4.2.3.2.India plasma fractionation market, by sector
      • 6.4.2.4.South Korea
      • 6.4.2.4.1.South Korea plasma fractionation market, by product
      • 6.4.2.4.2.South Korea plasma fractionation market, by sector
      • 6.4.2.5.Taiwan
      • 6.4.2.5.1.Taiwan plasma fractionation market, by product
      • 6.4.2.5.2.Taiwan plasma fractionation market, by sector
      • 6.4.2.6.Indonesia
      • 6.4.2.6.1.Indonesia plasma fractionation market, by product
      • 6.4.2.6.2.Indonesia plasma fractionation market, by sector
      • 6.4.2.7.Thailand
      • 6.4.2.7.1.Thailand plasma fractionation market, by product
      • 6.4.2.7.2.Thailand plasma fractionation market, by sector
      • 6.4.2.8.Malaysia
      • 6.4.2.8.1.Malaysia plasma fractionation market, by product
      • 6.4.2.8.2.Malaysia plasma fractionation market, by sector
      • 6.4.2.9.Vietnam
      • 6.4.2.9.1.Vietnam plasma fractionation market, by product
      • 6.4.2.9.2.Vietnam plasma fractionation market, by sector
      • 6.4.2.10.Rest of Asia-Pacific
      • 6.4.2.10.1.Rest of Asia-Pacific plasma fractionation market, by product
      • 6.4.2.10.2.Rest of Asia-Pacific plasma fractionation market, by sector
    • 6.4.3.Asia-Pacific market size and forecast, by product
    • 6.4.4.Asia-Pacific market size and forecast, by sector
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil plasma fractionation market, by product
      • 6.5.2.1.2.Brazil plasma fractionation market, by sector
      • 6.5.2.2.Kingdom of Saudi Arabia
      • 6.5.2.2.1.Kingdom of Saudi Arabia plasma fractionation market, by product
      • 6.5.2.2.2.Kingdom of Saudi Arabia plasma fractionation market, by sector
      • 6.5.2.3.Rest of LAMEA
      • 6.5.2.3.1.Rest of LAMEA plasma fractionation market, by product
      • 6.5.2.3.2.Rest of LAMEA plasma fractionation market, by sector
    • 6.5.3.LAMEA market size and forecast, by product
    • 6.5.4.LAMEA market size and forecast, by sector

CHAPTER 7:COMPANY PROFILES

  • 7.1.BAXTER INTERNATIONAL INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
  • 7.2.BIO PRODUCTS LABORATORY
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Key strategic moves and developments
  • 7.3.BIOTEST AG
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
    • 7.3.6.Key strategic moves and developments
  • 7.4.CSL LTD.
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
    • 7.4.6.Key strategic moves and developments
  • 7.5.GRIFOLS SA
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.LFB S. A
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
  • 7.8.OCTAPHARMA AG
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
    • 7.8.6.Key strategic moves and developments
  • 7.9.SANQUIN BLOOD SUPPLY FOUNDATION
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
    • 7.9.6.Key strategic moves and developments
  • 7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and developments